Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma
- PMID: 16794527
- DOI: 10.1097/01.tp.0000226069.66819.7e
Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma
Abstract
Background: Tumor number, size, and macrovascular invasion (MacroVI) are the most widely used predictors of survival after liver transplantation (LT) for hepatocellular carcinoma (HCC). We analyzed all patients undergoing LT for HCC at our center to establish the accuracy of preoperative clinical staging and to determine which patients have a higher probability of being understaged.
Methods: In all, 118 patients with confirmed HCC after LT from April 1991 to October 2004 at our institution were reviewed. All patients were monitored with serial imaging every 3 months to ensure their eligibility for LT within Milan criteria. Understaging in the 118 patients was defined as evidence on explant pathology that Milan criteria (TNM stage pT1 or pT2) had been exceeded.
Results: Five-year DFS was 78% with a recurrence rate of 15% after a median follow-up after LT of 30 months. On explant pathology, 43% (51/118) of patients exceeded Milan criteria and had a worse DFS (1 year, 95% vs. 87%; 3 year, 87% vs. 64%; P=0.03) compared to those who met LT criteria. Understaging was more likely in patients with imaging characteristics of > or = 2 tumor nodules (P=0.005) and tumor growth > 0.25 cm/month (P=0.02) and pathologic findings of vascular invasion (P=0.001) and bilobar tumors (P=0.002).
Conclusions: Preoperative imaging every 3 months while on the waiting list frequently understages HCC as assessed by explant pathology. Recurrence after LT often occurred in patients that were understaged. Improving the accuracy of clinical staging and inclusion parameters will ensure proper organ allocation and acceptable outcomes after LT.
Comment in
-
Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma.Transplantation. 2007 Feb 15;83(3):367-8. doi: 10.1097/01.tp.0000250657.24081.47. Transplantation. 2007. PMID: 17297420 No abstract available.
Similar articles
-
Liver transplantation in patients with hepatocellular carcinoma across Milan criteria.Liver Transpl. 2008 Mar;14(3):272-8. doi: 10.1002/lt.21368. Liver Transpl. 2008. PMID: 18306328
-
Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.Arch Surg. 2008 Feb;143(2):182-8; discussion 188. doi: 10.1001/archsurg.2007.39. Arch Surg. 2008. PMID: 18283144 Review.
-
Treatment before liver transplantation for HCC.Ann Surg Oncol. 2008 Apr;15(4):993-1000. doi: 10.1245/s10434-007-9787-8. Epub 2008 Jan 31. Ann Surg Oncol. 2008. PMID: 18236111 Review.
-
Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence.Liver Transpl. 2007 Apr;13(4):543-51. doi: 10.1002/lt.21078. Liver Transpl. 2007. PMID: 17394152
-
Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study.Transplantation. 2006 Jun 15;81(11):1532-41. doi: 10.1097/01.tp.0000209641.88912.15. Transplantation. 2006. PMID: 16770242
Cited by
-
Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues.Cancers (Basel). 2023 Nov 26;15(23):5593. doi: 10.3390/cancers15235593. Cancers (Basel). 2023. PMID: 38067299 Free PMC article. Review.
-
Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium.Am J Transplant. 2023 Nov;23(11):1771-1780. doi: 10.1016/j.ajt.2023.07.021. Epub 2023 Jul 31. Am J Transplant. 2023. PMID: 37532179 Free PMC article.
-
Cd34 Immunostaining Adds Specificity To Microvascular invasion Analysis in Hepatocellular Carcinoma.J Hepatocell Carcinoma. 2023 Jan 22;10:91-98. doi: 10.2147/JHC.S389836. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 36711001 Free PMC article.
-
Preoperative blood neutrophil count predicts survival in hepatocellular carcinoma patients with living donor liver transplantation.Korean J Transplant. 2020 Jun 30;34(2):92-99. doi: 10.4285/kjt.2020.34.2.92. Korean J Transplant. 2020. PMID: 35769348 Free PMC article.
-
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.JHEP Rep. 2022 Feb 2;4(5):100445. doi: 10.1016/j.jhepr.2022.100445. eCollection 2022 May. JHEP Rep. 2022. PMID: 35360522 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous